The 'Plavix case*' has revolutionized the management of Bristol-Myers Squibb. After the arrival on the market, ahead of expectations and attempts to 'blow it up', of the generic of one of Bms' best-selling champions, Plavix*, executive director Peter Dolan and general counsel Richard Willard left their positions, not quite spontaneously. James Cornelius has already been appointed executive director ad interim: a move that took place quickly to reassure investors, in a delicate moment for BMS, which is starting to focus on future growth profiles. From From Adnkronos 09-14-06
